Suzanne Rivera named new VP for research

Provost W.A. "Bud" Baeslack III announced, on November 4th, the appointment of Suzanne M. Rivera as Case Western Reserve´s new vice president for research, effective this month. Rivera, the university´s associate vice president for research since January 2011, emerged as the top choice after an extensive process involving campuswide nominations of internal university candidates. Since coming to CWRU, Rivera has distinguished herself through a commitment to collaboration and a focus on systems and processes.
Read more about her.


Research Matters

Click here to view previous editions of Research Matters and Research News and Updates.




Latest News

Research Newsletter
December 9, 2014  

SPARTA System Used for All External Funding Proposals

When seeking external support for research and other sponsored projects, a funding proposal must be entered in Sparta.

Sparta is not just for federal funding. It is also to be used for foundation funding, state awards, and contracts with industry sponsors. University personnel cannot negotiate agreements with industry until a funding proposal is entered in Sparta. In addition, a funding proposal must be entered online even when applications are made directly to a foundation.

Please consult with the Office of Research Administration or the SOM Office of Grants and Contracts if you need assistance entering a funding proposal online.

Office of Research Administration: https://research.case.edu/index.cfm

Office of Grants & Contracts in SOM: http://casemed.case.edu/grantscontracts/

Sparta System: https://sparta.case.edu/

 
The Cleveland Area Reliant IRB Review Process

The Cleveland Area Reliant Institutional Review Board (IRB) Review process includes participation by the Case Western Reserve University (CWRU) Social, Behavioral, and Educational Research (SBER) IRB, the Cleveland Clinic (CC) IRB, MetroHealth Medical Center (MHMC) IRB, and University Hospitals Case Medical Center (UHCMC) IRB. The process relies on executed IRB Authorization Agreements (IAA) between the institutions. These agreements document that all applicable human research subjects protection considerations will be made by one Institutional Review Board (IRB), which will be deemed the IRB of record. The IRBs of the other Cleveland area institutions will accept the approval of the IRB of record through the Reliant Review process. The goal is to eliminate duplication of effort and multiple applications for submission of the same protocol, and to encourage scientific collaboration among the affiliated institutions.

What types of studies are eligible for the Reliant Review Process?
Any type of human research study could be eligible for the Reliant Review process. These include but are not limited to investigator-initiated, federally-funded, foundation-supported, industry-sponsored, and non-funded studies.

The fundamental requirement is that a collaborating investigator must be named at each site where the research will occur. It is important for the Principal Investigator at the lead study site to work with the IRB of record throughout the Reliant Review Process to initiate acceptance of IRB approval at each collaborating site.

For further information, contact Kim Volarcik at (216) 368-0134 or kav6@case.edu.

 
Department of Defense

OFFICE OF STRATEGIC INITIATIVES - CALL FOR SUBMISSIONS

U.S. Army Medical Research and Materiel Command (USAMRMC) Broad Agency Announcement - BAA -15-1

Apply early. Funding is limited and subject to availability.
The BAA is continuously open, and accepts proposals on a rolling basis. Pre-proposals may be submitted and will be evaluated at any time throughout the year.

Scope: The USAMRMC's mission is to provide solutions to medical problems of importance to the American warfighter. Projects must pertain to at least one of the research areas of interest outlined in the BAA.

Funding: Budgets are not capped and must reflect the scope of the work. Funding can be requested for up to 5 years.

Areas of interest:
1. Military Infectious Diseases Research Program
2. Combat Casualty Care Research Program
3. Military Operational Medicine Research Program
4. Clinical and Rehabilitative Medicine Research Program
5. Medical Biological Defense Research Program
6. Medical Chemical Defense Research Program
7. Medical Simulation and Information Sciences Research Program 8. Radiation Health Effects Research Program
9. Special Investment Areas/Innovation Funding

Office of Strategic Initiatives (OSI): Case School of Medicine's OSI can work with you to make sure that you meet the current goals and objectives of the USAMRMC that is paramount for your success. OSI can assist you in preparing a competitive proposal and can help guide your efforts from the first draft of the pre-proposal to submission of the full application.

Timeline: Invitation to submit a Full proposal will be given within 90 days of submission of the pre-proposal. An additional 90 days is provided to the applicant to complete the full application. Allow for at least 6 months between submission of the whitepaper to submission of the full application.

Contact us: If you are planning on submitting a pre-proposal, have questions, or would like more information - contact OSI Project Manager Irene Shaland - ixs75@case.edu - 216.368.4970

 
Shipping Abroad in Compliance with Export Regulations

The federal export control laws can apply when regulated items are being shipped abroad. Before shipping a device, materials, or other items abroad, CWRU personnel should contact either the Environmental Health and Safety Office or the Compliance Office so that an employee trained in export compliance can determine whether an export license is needed prior to making the shipment.

These are the steps that all CWRU researchers should follow when planning to make an outgoing international shipment of items or materials:

  1. The CWRU Principal Investigator works with the CWRU Technology Transfer Office (“TTO”) to determine whether a Material Transfer Agreement (“MTA”) is needed prior to the shipment. The CWRU PI initiates this by submitting a completed MTA Review Form found at https://research.case.edu/forms.cfm#tech_mgt.
  2. If the Technology Transfer Office determines that an MTA is needed between CWRU and the overseas organization to receive the items or materials, the Principal Investigator and TTO work together to put it in place. Once the MTA is completed and signed by CWRU and the recipient organization, the Technology Transfer Office will forward a copy of the final contract to the PI. The PI should keep a copy of the final MTA for easy reference. Note that MTAs not only help to ensure compliance with the federal export laws, but they also protect investigators’ intellectual property rights.
  3. Before making the shipment overseas, the PI should contact the CWRU Environmental Health and Safety Office. This step is necessary so that the Environmental Health and Safety Office can analyze the contents of the shipment in light of the export regulations and determine whether the shipment can proceed immediately, or whether federal pre-authorization is needed. If the Technology Transfer Office determined that an MTA was needed, then the PI should provide Environmental Health and Safety with a copy of the signed MTA so that it can match the requested shipment with the formal contract.
If you have questions on how the export regulations impact specific international shipments, contact the Compliance Office: Lisa Palazzo, Director of Export Control and Privacy Management, at 368-5791, or Boyd Kumher, University Chief Compliance, Export Control and Privacy Management Officer, at 368-0833; or email exportcontrol@case.edu.

For more information on the export control regulations, including the full text of CWRU’s Export Control Policy Statement, visit http:www.case.edu/compliance/exportcontrol/.

Questions regarding Material Transfer Agreements (MTAs), should be addressed to Andrew Jarrell in the Technology Transfer Office, Andrew.jarrell@case.edu, 368-1401.

 
New Policy from NIH to Balance Sex in Cell and Animal Studies

NIH announced last week a new policy requiring "a balance of male and female cells and animals in preclinical studies in all future applications." In this week's Nature, Janine Clayton and Francis Collins write, "The over-reliance on male animals and cells in preclinical research obscures key sex differences that could guide clinical studies. And it might be harmful: women experience higher rates of adverse drug reactions than men do. Furthermore, inadequate inclusion of female cells and animals in experiments and inadequate analysis of data by sex may well contribute to the troubling rise of irreproducibility in preclinical biomedical research."

Read more at: http://ow.ly/wSqy6.

 

If you have news or information that you wish to have included in this update, please send it via e-mail to Tracy Wilson-Holden at tracy.wilson-holden@case.edu no later than 5 pm on the Monday of the week that the update is to be distributed. If you know of individuals who may be interested in receiving this update, please forward this e-mail to them. To subscribe or unsubscribe to Case Research News, email your request to Tora Williams at tora.williams@case.edu.

Please note: At the time of this transmission, all links functioned. However, Case Research News cannot guarantee that the information will not move or be deleted.